Contract manufacturing: News in brief
Therapure opens doors for business
Canada-based Therapure Biopharma has begun work on its first contracts with customers in biopharmaceutical development and manufacturing.
The company’s 130,000 sq ft current good manufacturing practice (cGMP) compliant facility in Ontario, Canada has begun manufacturing complex biological products for its clients.
By employing staff with an understanding of the manufacture, marketing and business opportunities for protein-based therapeutics, Therapure believes it can offer clients services beyond the traditional contract manufacturing remit.
Thomas Wellner, Therapure’s CEO, said: "We are more than just a contract manufacturing organization (CMO).
“The company's scientific, manufacturing, and downstream purification expertise, combined with an intimate understanding of advanced biology, complex proteins, and the regulatory requirements for biological drugs, enables us to be a drug development partner with our clients."
It is the company’s aim to provide a “one-stop shop for pilot and commercial scale protein/active pharmaceutical ingredient (API) production, processing, filling, and finishing.”
Hollister-Stier poised to complete expansion
Hollister-Stier Laboratories, a contract manufacturer and aseptic processor/filler of commercial and clinical-trial sterile injectables, has outlined its expansion plans.
The US-based company is close to completing a $41m facility expansion that will dramatically increase laboratory and production capacity.
Upon completion the site will have 130,000 sq ft of manufacturing space, with equipment also being upgraded to add a second high-speed commercial aseptic filling line.
Hollister-Stier’s capabilities cover aseptic processing of lyophilised and liquid products, vaccines, biological proteins, microspheres, liposomes, suspensions and diluents.
West expands manufacturing facility
West has completed expansion work at its Kinston, North Carolina manufacturing facility, giving the company additional compounding and custom manufacturing capacity. The site will create more than 150 new jobs.
Dow expands printing portfolio
Dow Pharmaceutical Sciences has expanded its internal clinical labeling printing capabilities by adding non-smear thermal transfer printers to its facility.
In addition Dow has installed software that allows for uploading and printing of random codes, allowing the company to print any single panel label.
Dow believes this will decrease cost, allow for timely label revisions and speed-up re-supply for its clients in the biopharmaceutical industry.
